37.19

0.03% 0.010

Pre-market: 36.65 -0.54 -1.45%

Agios Pharmaceuticals Inc (AGIO)

Overview News Price History Option Chain Financials Discussions Forecast

Agios Pharmaceuticals Inc stock is traded at $37.19, with a volume of 931.10K. It is up +0.03% in the last 24 hours and up +8.77% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Previous Close:

$37.18

Open:

$37.22

24h Volume:

931.10K

Relative Volume:

0.79

Market Cap:

$2.22B

Revenue:

$66.05M

Net Income/Loss:

$-422.60M

P/E Ratio:

-5.1289

EPS:

-7.251

Net Cash Flow:

$-384.73M

1W Performance:

+18.74%

1M Performance:

+8.77%

6M Performance:

+44.48%

1Y Performance:

-11.64%

1-Day Range:

$0.00

1-Week Range:

$31.61

$37.74

52-Week Range:

$22.24

$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name

Agios Pharmaceuticals Inc

Sector

Healthcare (1051)

Industry

Biotechnology (594)

Phone

617-649-8600

Address

88 SIDNEY STREET, CAMBRIDGE, MA

Employee

540

Twitter

@AgiosPharma

Next Earnings Date

2026-11-05

Latest SEC Filings

AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AGIO Agios Pharmaceuticals Inc	37.19	2.22B	66.05M	-422.60M	-384.73M	-7.251
VRTX Vertex Pharmaceuticals Inc	535.17	135.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	819.09	84.33B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	202.63	80.90B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	875.76	55.07B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	382.27	43.24B	5.76B	514.49M	1.10B	4.4813

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Reiterated	H.C. Wainwright	Buy
Nov-24-25	Initiated	Truist	Buy
Nov-20-25	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-24-25	Initiated	H.C. Wainwright	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight
Nov-17-22	Upgrade	Goldman	Sell → Neutral
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-21	Initiated	BofA Securities	Buy
Jul-30-21	Downgrade	Goldman	Neutral → Sell
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
May-23-19	Resumed	Goldman	Neutral
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy
Apr-11-18	Reiterated	Credit Suisse	Outperform
Feb-15-18	Reiterated	Needham	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-10-17	Reiterated	Needham	Buy
Aug-08-17	Reiterated	SunTrust	Buy
Aug-02-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-17	Downgrade	Janney	Buy → Neutral
Jan-17-17	Upgrade	Oppenheimer	Perform → Outperform
Oct-24-16	Initiated	Needham	Buy
Jun-13-16	Upgrade	JP Morgan	Neutral → Overweight
May-18-16	Reiterated	SunTrust	Buy

View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

Oct 21, 2026

DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line - Zacks Investment Research

Oct 21, 2026

Oct 19, 2026

Four FDA Decisions in Two Weeks: GSK's Hepatitis B Drug Leads the Pack as Inovio Shares Have Already Fallen Over 40% This Year - BigGo Finance

Oct 19, 2026

Why Did Agios Pharmaceuticals (NASDAQ:AGIO) Rise 7.41% Before a November 1 FDA Decision on Mitapivat in Sickle Cell Disease? - kalkine.ca

Oct 19, 2026

GSK, INO, AGIO And Sun Pharma Await Key FDA Rulings In October That Could Shape Their Drug Pipelines - Stocktwits

Oct 19, 2026

GlaxoSmithKline (GSK.US), Inovio (INO.US), and Agios (AGIO.US) are among a cluster of companies awaiting review, as U.S. innovative drugs enter an FDA approval window. - Moomoo

Oct 19, 2026

Oct 17, 2026

Why Is AGIO Stock Falling Today? - Stocktwits

Oct 17, 2026

Oct 16, 2026

Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research

Oct 16, 2026

Oct 15, 2026

Cantor Fitzgerald reiterates Agios Pharma stock rating ahead of PDUFA By Investing.com - Investing.com South Africa

Oct 15, 2026

Oct 14, 2026

4 High-Risk Stocks Built for Big Returns - The Motley Fool

Oct 14, 2026

Oct 09, 2026

Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales - Yahoo Finance

Oct 09, 2026

Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date - Yahoo Finance

Oct 09, 2026

Oct 06, 2026

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView

Oct 06, 2026

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - Zacks Investment Research

Oct 06, 2026

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView

Oct 06, 2026

Oct 02, 2026

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research

Oct 02, 2026

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Yahoo Finance

Oct 02, 2026

Sep 22, 2026